普雷沃特拉介质通过ISG15升级促进OSCC的进展:干预的新目标
Yao Qin1, Zhiyuan Li1, Ting Liu1
1Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, 30 Zhongyang Road, Nanjing, 210008, China.
Journal of cancer research and clinical oncology
|April 21, 2024
概括
普雷沃特拉中间体感染通过上调ISG15.促进口腔状细胞癌 (OSCC) 的进展. 抗生素治疗逆转了这些影响,这表明P.intermedia是OSCC的潜在治疗点.
科学领域:
- 口腔瘤学 在口腔瘤学
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
背景情况:
- 与牙周炎相关的细菌,包括 Porphyromonas gingivalis 和 Fusobacterium nucleatum,与口腔状细胞癌 (OSCC) 风险有关.
- 常见的牙周病原体Prevotella intermedia (P.intermedia) 在OSCC中越来越多地被发现,可能会影响其发展和进展.
研究的目的:
- 调查P.intermedia对OSCC进展的影响.
- 确定抗生素的使用是否可以逆转P.intermedia对OSCC的影响.
主要方法:
- 使用了OSCC的小鼠异种移植模型.
- 小鼠接受了PBS (对照),P.中间体或P.中间体加抗生素 (ABX) 的治疗.
- 瘤生长,侵袭,血管新生,转移,血清细胞因子和免疫细胞透被分析使用组织病理学,ELISA和免疫组织化学 (IHC). 转录组测序确定了差异性的基因表达.
主要成果:
- 中间P.显著增强瘤生长,入侵,血管新生和转移.
- 抗生素治疗抵消了P.intermedia.的前瘤性作用.
- 中间感染上调调节了干扰素刺激基因15 (ISG15),该基因与瘤进展标志物正相关,与CD4+/CD8+T细胞透负相关.
结论:
- 内P.中间体感染会加剧OSCC的进展,可能是通过ISG15上调调节.
- 这项研究突出了OSCC.中P.intermedia的新型致病机制.
- P.intermedia可能是OSCC预防和治疗的未来治疗点.
相关概念视频
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K


